Growth opportunity Emerging immuno-oncology startup with a global investor-backed platform and ongoing preclinical to clinical development offers a foothold for sponsored research collaborations, strategic partnerships, and potentially early-access or co-development deals.

Executive engagement Recent leadership hires in business and development roles signal a readiness to form partnerships; target their CBO and CDO teams for alliance discussions, licensing conversations, and joint submissions with potential CRO/CMO collaborators.

Funding signal Significant funding rounds and Series B backing demonstrate capital availability and a readiness to scale; align outreach around high-value collaborations, out-licensing opportunities, and milestone-based partnerships to de-risk investment.

Product focus Lead program OMX-0407 an oral SIK3 inhibitor positions iOmx in next-generation immune checkpoint space; explore opportunities in companion diagnostics, biomarker development, and combination trial support with pharma to accelerate clinical programs.

Geographic focus Martinsried/Munich base with international investors suggests openness to European and global partnerships; propose regional partnership models, clinical trial site access, supply chain optimization, and regulatory strategy co-development.